Research Funded by the National MS Society Suggests Novel Path for Regulation of MS
August 7, 2019
A Stanford team has found that immune cells known for dousing infection or cancer might be exploited to stop the immune response that drives MS. The researchers injected mice with MS-like disease with proteins that activate and increase these suppressive CD8+ T cells, resulting in decreased inflammatory activity, and decreased disease activity. Results were similar in blood samples obtained from people with MS. The team is working further to determine if such cells could be mobilized as a novel treatment for MS and other immune mediated diseases.
This research was supported by a Career Transition Award from the National MS Society to Naresha Saligrama, PhD, and by funding from the Howard Hughes Medical Institute, the National Institute of Allergy and Infectious Diseases, and the Simons Foundation.
Read more from Stanford University
Read a scientific summary of the paper in Nature
Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.